Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Memantine, an NMDA antagonist, is effective for moderate to severe Alzheimer’s disease. Objective: Determine whether memantine improves cognitive performance (CP) among subjects with multiple sclerosis (MS) and cognitive impairment (CI). Methods: This double-blind, randomized, placebo-controlled trial (Clinicaltrials.gov NCT00300716) compared memantine 10 mg twice a day (4 week titration followed by 12 weeks on the highest tolerated dose) with placebo. The primary outcome was the change from baseline to exit on the Paced Auditory Serial Addition Test (PASAT) and the California Verbal Learning Test-II (CVLT-II) Long Delay Free Recall (LDFR). Secondary outcomes included additional neuropsychological tests; self-report measures of quality of life, fatigue, and depression; and family/caregiver reports of subjects’ CI and neuropsychiatric symptoms. Results: The differences between the groups on the change on the PASAT (placebo—memantine = 0.0 correct responses, 95% CI 3.4, 3.4; p = 0.9) and on CVLT-II LDFR (placebo—memantine =—0.6 words, 95% CI —2.1, 0.8; p = 0.4) as well as on the other cognitive tests were not significant. Subjects on memantine had no serious adverse events (AEs) but had more fatigue and neurological AEs as well as, per family members’ reports, less cognitive improvement and greater neuropsychiatric symptoms than subjects on placebo. Conclusion: Memantine 10 mg twice a day does not improve CP in subjects with MS, ages 18—65, without major depression, who have subjective cognitive complaints and perform worse than one SD below the mean on the PASAT or on the California Verbal Learning Test-II (total recall or delayed free recall).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568 · cited 1×
“Since self-report measures can be unreliable in people with CI, we also included reports from the subject’s closest family member or caregiver using the MS Neuropsychological Screening Questionnaire (MSNSQ)(21) and the Modified Neuropsychiatric Inventory (MNPI).(22,23) In the MSNSQ the caregiver or family member repor…”
MethodMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909 · cited 1×
“In theory memantine allows neurons to continue to transmit signals while it reduces the noise created by abnormally high levels of extracellular glutamate.(24) Glutamate transport is altered in patients with MS(25,26) and the levels of glutamate, measured by MR spectroscopy, are known to be elevated in the normal whit…”
BackgroundPredicting neuropsychological abnormalities in multiple sclerosis
Benedict, R. H. B., & Zivadinov, R. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.05.020 · Cited by 73
Cited by
Cognitive Dysfunction in Multiple Sclerosis
Guimarães, J., & Sá, M. J. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00074 · Cited by 427
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310
Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis
Mandolesi, G., Gentile, A., Musella, A., Fresegna, D., De Vito, F., Bullitta, S., Sepman, H., Marfia, G. A., & Centonze, D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.222 · Cited by 286
Assessment and impact of cognitive impairment in multiple sclerosis: An overview
Macías Islas, M. Á., & Ciampi, E. (2019) · Biomedicines · doi:10.3390/biomedicines7010022 · Cited by 144
“Regarding memantine, similar contradictory findings were reported in a small number of studies prevailing negative outcomes for this drug [131].”
ResultMechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities
Macrez, R., Stys, P. K., Vivien, D., Lipton, S. A., & Docagne, F. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30165-x · Cited by 127
Metadata
- Authors
- Lovera, J., Frohman, E., Brown, T., Bandari, D., Nguyen, L., Yadav, V., Stuve, O., Karman, J., Bogardus, K., Heimburger, G., Cua, L., Remingon, G., Fowler, J., Monahan, T., Kilcup, S., Courtney, Y., McAleenan, J., Butler, K., Wild, K., Whitham, R., & Bourdette, D.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2010-05-18
- Volume
- 16
- Issue
- 6
- Pages
- 715-723
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2066108884
- Cited by
- 105
- References
- 4
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. https://app.cochat.ai/papers/10.1177/1352458510367662
- The paper
- Lovera, J., Frohman, E., Brown, T., Bandari, D., Nguyen, L., Yadav, V., Stuve, O., Karman, J., Bogardus, K., Heimburger, G., Cua, L., Remingon, G., Fowler, J., Monahan, T., Kilcup, S., Courtney, Y., McAleenan, J., Butler, K., Wild, K., . . . Bourdette, D. (2010). Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458510367662
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.